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Background: Endothelial cells line the luminal surface of blood vessels and form a barrier between the blood and
other tissues of the body. Ets variant 2 (ETV2) is transiently expressed in both zebrafish and mice and is necessary
and sufficient for vascular endothelial cell specification. Overexpression of this gene in early zebrafish and mouse
embryos results in ectopic appearance of endothelial cells. Ectopic expression of ETV2 in later development results
in only a subset of cells responding to the signal.
Findings: We have examined the expression pattern of ETV2 in differentiating human embryonic stem cells (ESCs)
to determine when the peak of ETV2 expression occurs. We show that overexpression of ETV2 in differentiating
human ESC is able to increase the number of endothelial cells generated when administered during or after the
endogenous peak of gene expression.
Conclusions: Addition of exogenous ETV2 to human ESCs significantly increased the number of cells expressing
angioblast genes without arterial or venous specification. This may be a viable solution to generate in vitro
endothelial cells for use in research and in the clinic.
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Embryonic stem cells (ESCs) are pluripotent and thus
have the ability to differentiate into all cell types of the
body. Previous groups have derived endothelial cells, the
cells that line blood vessels, from mouse ESCs (mESCs)
and human ESC (hESCs) and shown that they are func-
tional in in vivo assays [1-7]. In many differentiation
protocols, only a small percentage of cells differentiate
into endothelial cells; however, large quantities of cells
are required for potential downstream bioengineering
applications [1,2].
Expression of Etv2 is required for the proper forma-
tion of the vasculature in fish and mammals [8-10].
Overexpression of Etv2 in differentiating mESCs has
been shown to be effective at increasing the number of
endothelial cells [9,11]. Inducible expression of Etv2 over
a short period of time concurrent with endogenous* Correspondence: shuolin@ucla.edu
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unless otherwise stated.expression is sufficient to increase the population of
endothelial cells from 8% to 70% [9]. Recent work infecting
hESCs with ETV2 expressing virus showed that roughly
40% of the infected cells could become endothelial-like
under modified culture conditions that also support hESC
self-renewal [12].
We wanted to determine if addition of exogenous
ETV2 during differentiation could induce endothelial
cells from hESCs more effectively than addition before
differentiation. First, we determined the timing of the
expression of endogenous ETV2 in a hESC differenti-
ation model. hESCs were differentiated into endothelial
cells using a method that utilized both embryoid body
(EB) and adherent stages and were similar to those re-
ported previously (Figure 1A) [1,3]. The cells were colla-
genase IV digested into clusters and allowed to form EBs
overnight in mTeSR1 media in low adherence plates for
24 h. The EBs were collected by gravity and the medium
was replaced with mTeSR1 supplemented with 10 ng/ml
BMP4. Four days later, the EBs were digested to single
cells with Accutase and plated on Matrigel-coated platesal. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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Figure 1 Differentiation of hESC to endothelial cells. (A) Diagram of the differentiation protocol. (B–D) Semi-quantitative real-time PCR analysis
of gene expression in cells from days 0 to 8 of differentiation. Genes examined: (B) BRACHYURY and ETV2. (C) VE-CADHERIN and CD-31. (D) KDR and
CD34. (E) Flow cytometry analysis of day 7 differentiation of hESC. Percentages shown represent averages from five experiments with standard
deviations. (F) Quantitative analysis of data in panel (E). Immunofluorescence of day 7 of differentiation for CD31 (G) and VE-CADHERIN (H).
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25 ng/ml VEGF and 20 ng/ml bFGF2. To determine the
timing of gene expression, we collected RNA samples
from days 0 to 8 of hESC differentiation. Semi-quantitativereal-time PCR performed on cDNA generated from the
extracted RNA showed that BRACHYURY expression, a
marker of mesoderm specification, peaked on day 2 while
ETV2 expression peaked on day 5 of differentiation
Figure 2 (See legend on next page.)
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Figure 2 Introduction of exogenous ETV2 increases the percentage of endothelial cells generated during differentiation. (A) Construct
used to generate virus for introduction of ETV2 to hESC. (B–D) Flow cytometry for YFP and VE-CADHERIN. Left panels of each subset show YFP
expression in infected cells. Right panels of each subset show VE-CADHERIN expression within YFP+ population. Percentages represent an average
from three (B, D) or six experiments (C) and cell counts represent and average from three (B,D) or four experiments (C). Cells were infected/analyzed
on days −7i/+7a (B), +4i/+7a (C), and +1i2/+15a (D). Cell counts and percentages are calculated from cells gated to be non-debris, alive, and single
cells. (E) Graphical summary of flow cytometry for infection efficiency in cells infected and analyzed on days indicated. Error bars indicate
standard deviation. (F) Graphical summary of results of flow cytometry for VE-CADHERIN of YFP expressing virally infected cells. Error bars
indicate standard deviation.
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pression of Brachyury and Etv2 in the mesoderm of mice,
where the Brachyury expression precedes a wave of
Etv2 expression by 2 days [9,13,14]. The endothelial
markers VE-CADHERIN, CD31, KDR, and CD34 showed
an increase on day 5 that continued for the next 3 days
(Figure 1C,D).
To determine the percentage of endothelial-like cells,
we analyzed the surface expression of VE-CADHERIN/
CDH5, CD31, FLK1/KDR, and CD34 on day 7 of differ-
entiation by flow cytometry. The greatest number of
cells expressed KDR (40.4%) (Figure 1E,F). This agrees
with previous reports in the mouse and human systems
where KDR marked endothelial cells as well as a large
population of mesodermal precursors and undifferen-
tiated hESCs [15,16]. VE-CADHERIN (8.5%), CD31
(4.8%), and CD34 (13.8%) were expressed on similar-sized
populations of cells and the majority of these cells showed
overlap with the three markers (Figure 1E,F). To deter-
mine if the cells differentiated in clusters or from scattered
single cells, we stained the cells in situ on day 7 of differ-
entiation. Clusters of CD31 and VE-CADHERIN cells
were seen (Figure 1G,H).
We constructed two lentiviral vectors to express either
mCherry, as a control, or an ETV2-mCherry fusion protein
(Figure 2A). Based upon transient transfection experiments,
we found that the ETV2-mCherry fusion protein was local-
ized to the nucleus but difficult to visualize by either mi-
croscopy or flow cytometry (data not shown). To ensure
that we could identify virally infected cells, we co-expressed
yellow fluorescent protein (YFP) with the mCherry or
ETV2-mCherry proteins (Figure 2A). YFP expression was
used as proxy for mCherry and ETV2-mCherry expression
for the remainder of the experiments.
Previous studies in the murine system have examined
the effect of exogenous Etv2 on differentiating mESCs
and demonstrated that up to 70% of the differentiating
cells were responsive to exogenous Etv2 [9]. mESCs
were induced to transiently express exogenous Etv2 con-
currently with endogenous Etv2 in differentiating embry-
oid bodies [9]. Experiments in hESCs have tested the
ability of exogenous ETV2 to induce endothelial cells
from undifferentiated hESCs and from a FLK1+ subset
of differentiated hESCs [12,17]. We wanted to examinewhether the addition of ETV2 at different stages of
hESC differentiation would result in differing yields of
endothelial-like cells. We infected cells either before dif-
ferentiation (−7i/+7a) (Figure 2B) or at day 4 (+4i/+7a)
(Figure 2C) of differentiation and analyzed the cells
7 days after the initiation of differentiation by flow cy-
tometry for YFP and VE-CADHERIN expression. The
infection efficiency of −7i/+7a cells was low in comparison
to that of +4i/+7a, despite using a higher multiplicity of in-
fection (MOI), 20 vs 2, respectively (Figure 2B,C,E). This
agrees with previous publications demonstrating the low
infection efficiency of hESCs [18,19]. In control virus-
infected cells at each time point, a similar percentage of
VE-CADHERIN positive cells (~10%) were observed com-
pared to that in uninfected cells (Figure 2B,C,F). In the
population infected with the ETV2-mCherry virus before
differentiation, 22.9% of the cells were positive for VE-
CADHERIN after differentiation, a twofold increase over
the control (Figure 2B,C,F). This did not result in an
absolute increase in endothelial-like cells as the slight
increase in VE-CADHERIN-positive cells infected with
ETV2-mCherry virus was counteracted by the decreased
infection efficiency of these cells (Figure 2B). The apparent
lack of response to ETV2 in cells infected before differen-
tiation may be due to the loss of cells that responded to
ETV2. Cells that gained an endothelial-like phenotype in
the 7 days after infection would have been excluded dur-
ing the EB generation step of the differentiation protocol.
ETV2 administered during differentiation had a much
more pronounced effect. Of the cells infected during
differentiation, 60.4% were VE-CADHERIN positive on
day 7 resulting in a sixfold increase over control cells
(Figure 2B,C,F). This is comparable to what was seen in
mESC culture [9]. The absolute number of cells that
expressed VE-CADHERIN was significantly higher follow-
ing ETV2-mCherry infection, increasing from an average
of 645/10,000 cells in control conditions to 4,141/10,000
cells in ETV2 overexpression conditions (Figure 2C).
Our previous work in zebrafish found that only a few
cell types are responsive to exogenous etv2 after 24 h of
differentiation and unresponsive by 48 h [20]. Work per-
formed in vivo in conditionally transgenic Etv2 mice
showed that cells committed to the somitic or neural line-
ages were unresponsive to exogenous Etv2 [21]. Infection
Figure 3 (See legend on next page.)
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Figure 3 Characterization of ETV2-induced endothelial cells. (A,B) Semi-quantitative real-time PCR on sorted YFP+ VE-CADHERIN+ cells from
day 7 of differentiation and infected in day 4 for arterial (A) and venous (B) markers. (C,D) Immunofluorescence against CD31 and VE-CADHERIN
on sorted ETV2-mCherry-infected VE-CADHERIN-positive cells cultured for 7 days. Scale bar = 20 μm. Upper panels are anti-CD31 (C) or VE-CADHERIN
(D) primary antibody and appropriate secondary. Lower panels, secondary antibody only. (E) Network formation on Matrigel of sorted ETV2-mCherry
VE-CADHERIN positive cells grown for 7 days in culture. The cells were imaged 8 h after plating. Scale bar = 1 mm. (F) Flow cytometry on
sorted ETV2-mCherry-infected VE-CADHERIN-positive cells cultured for 7 days. The cells were analyzed for YFP expression and VE-CADHERIN
expression. Percentages are an average of two experiments.
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an ETV2 virus in combination with FLI1 and ERG1 vi-
ruses only modestly induced endothelial genes [17].
Based upon this knowledge, we anticipated that infec-
tion of differentiating hESCs with an ETV2-expressing
virus at time points later than the peak of endogenous
expression would result in decreasing percentages of
cells responding to the exogenous signal. The cells were
infected at day 12 of differentiation and analyzed for
VE-CADHERIN expression 3 days after infection. Sur-
prisingly, the surface expression of VE-CADHERIN was
not significantly different in +12i/+15a ETV2-mCherry-
infected cells from +4i/+7a ETV2-infected cells demon-
strating that the cells had not lost responsiveness to
ETV2 as predicted (Figure 2D,F).
We wanted to further characterize the endothelial-like
cells that were generated from our viral transductions.
Comparable numbers of ETV2-mCherry and control in-
fected cells were sorted for YFP and VE-CADHERIN ex-
pression on day 7 of differentiation. RNA was isolated
from these cells to determine the venous or arterial
identity of these cells. Semi-quantitative real-time PCR
performed on cDNA derived from this RNA demon-
strated that cells infected with the ETV2-mCherry virus
expressed lower levels of both arterial and venous
markers (Figure 3A,B). This indicates that cells express-
ing very high levels of ETV2 did not differentiate into ar-
terial or venous endothelium and likely remain in an
angioblast state. In vivo and in vitro data has shown that
constitutive expression of ETV2 causes endothelial cells
to remain in a more primitive state [12,21].
Sorted YFP+ VE-CADHERIN+ cells were grown on
gelatin in endothelial media supplemented with 20 ng/ml
bFGF, 25 ng/ml VEGF165, and 10 μg/ml TGFβ inhibitor
SB431542. The ETV2-infected cells proliferated faster than
the control cells and maintained a uniform morphology
(data not shown). An increased level of proliferation has
been shown previously in cells constitutively expressing
exogenous ETV2 [17]. After 7 days of growth, the vast
majority of ETV2-infected cells all maintained CD31 and
VE-CADHERIN expression by immunostaining and flow
cytometry (Figure 3C,D,F). These cells formed networks
within 3 h of plating on Matrigel with optimal tube net-
work formation at 8 h (Figure 3E).Practical and ethical reasons prevent us from examin-
ing the timing and role of expression of ETV2 in early
human fetal samples. We have examined the timing of
ETV2 expression in differentiating human ESCs and
found that its expression in relation to other develop-
mental genes is similar to that found in the developing
mouse in vivo and in vitro. In our method of infection
during mesoderm-directed differentiation, 60% of the
ETV2 expressing cells were able to respond. This is simi-
lar to the level found in mESCs [9].
Clinical and preclinical trials are being performed that
use endothelial cells from various sources to aid in the
recovery from many vascular and cardiac conditions
[22-24]. A common roadblock in these procedures is a
lack of source allogeneic endothelial cells. Other clinical
work is being performed to generate vascular structures
that can then be seeded with endothelial cells prior to
transplant into patients [25]. Use of induced pluripo-
tent cells derived directly from the patient would allow
for histocompatible graft material being available for
transplant. Addition of ETV2 is a viable strategy for
increasing the yield of endothelial-like cells from these
sources. Any cells transplanted into a patient would need
to be derived through non-integrating viral or non-viral
methods. These methods would result in a pulse of
gene expression corresponding to the time of treat-
ment. Using these methods would generate transient
ETV2 expression. This might allow the endothelial-like
cells generated during ETV2 expression, demonstrated
in this report, to more fully differentiate into arterial
and venous endothelial cells upon loss of ETV2 ex-
pression. Recent work has shown that administration
of ETV2 and GATA2 mRNA is able to convert hESCs
to hematopoietic cells. Addition of ETV2 mRNA alone
may be able to generate endothelial cells with an un-
altered genome that could be used for transplantation into
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